Results 91 to 100 of about 14,984 (246)

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Psychedelics and the Spiritual Path - Critical Voices and Considerations [PDF]

open access: yes, 2016
‘I undertake the training to abstain from intoxicants which cloud the mind’ (the Fifth Precept of Buddhism) This paper was originally presented as a presentation at of the British Psychological Society’s Transpersonal Psychology 19th annual conference - ‘
Cohen, E
core  

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Drug Laws, Ethics, and History [PDF]

open access: yes, 2019
In this paper, I present and criticize several historical arguments in favour of prohibition and criminalization of illicit psychoactive substances. I consider several versions of Charles Brent’s argument from drug harms and an argument
Greif, Adam
core  

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito   +6 more
wiley   +1 more source

Psychedelic medicine: The biology underlying the persisting psychedelic effects

open access: yesMedical Hypotheses, 2019
Psychedelic substances have regained interest as therapeutic agents in the treatment of stress-related disorders. The effects seem to be of persisting nature even after a single dose. Also in lower than 'regular' recreational doses, so-called micro-doses, without the typical effects on consciousness, users report beneficial effects on cognitive ...
openaire   +3 more sources

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi   +10 more
wiley   +1 more source

Integrating Psychedelics into Groupwork: A Culturally Responsive Model for the Counseling Profession

open access: yesPsychoactives
Psychedelics, combined with talk therapy, indicate promise with challenging clients, such as those struggling with PTSD. Furthermore, groupwork, with the emphasis on social connections, can be an effective modality.
Isaac Burt
doaj   +1 more source

Recent changes in drug abuse scenarios : The new/novel psychoactive substances (NPS) phenomenon [PDF]

open access: yes, 2018
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Peer ...
Schifano, Fabrizio
core   +2 more sources

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy